Today's Technical View on Unitedhealth Group, Aetna, AstraZeneca, Oncothyreon, and Zogenix

LONDON, March 1, 2013 /PRNewswire/ --

The Healthcare industry is undergoing a major overhaul after the Supreme Court last year upheld President Obama's Affordable Care Act (ACA). While critics of the healthcare reform say that it increase costs for the healthcare industry, proponents of ACA note that the increase in the number of insured individuals will ultimately benefit the industry. Meanwhile, healthcare companies such as UnitedHealth Group Inc. (NYSE: UNH), Aetna Inc. (NYSE: AET), AstraZeneca Plc (NYSE: AZN), Oncothyreon Inc. (NASDAQ: ONTY) and Zogenix Inc. (NASDAQ: ZGNX) are adapting to the changing market dynamics. On Thursday, Healthcare sector managed to post modest gains even as the broad market declined. StockCall initiated free in-depth technical analysis on UNH, AET, AZN, ONTY and XX which are currently available upon sign up at

Shares of UnitedHealth Group Inc. edged lower in Thursday's trading session, extending their losses for the week. The stock closed 0.78% lower at $53.45 on volume of 5.88 million. It has now fallen more than 1.80% this week. Year-to-date, UnitedHealth's shares are down nearly 1.50%, underperforming the S&P 500, which has gained more than 6%. The company's shares currently have support at around $53. The stock has been facing stiff resistance at around $55.50. Technical indicators for the stock are currently giving strong bearish signals. Sign up for the free technical analysis on UNH at  

Shares of diversified healthcare benefits company, Aetna Inc., also slipped in Thursday' trading session. The stock closed 0.72% lower at $47.19 on above average volume of 3.42 million. Despite the pullback yesterday, Aetna's shares have gained more than 1% in the last three trading sessions. Its shares are currently trading well above their 200-day moving average. However, recent volume activity suggests that the market sentiment is bearish on the stock. Its shares are currently trading on a P/E ratio of 9.85. The stock has a dividend yield of 1.70. Download the free report on AET by registering at  

Shares of AstraZeneca Plc ended marginally lower in Thursday's trading session. The stock closed 0.42% lower at $45.44 on volume of 1.72 million. The stock has gained 0.58% so far this week. Year-to-date, AstraZeneca Plc shares have underperformed the broad market, falling nearly 4%. AstraZeneca Plc's MACD has just crossed the signal line on the upside, which is a bullish signal. The stock is currently facing resistance at around $46.50. It has support at around $45. The free report on AZN can be downloaded by signing up now at  

Shares of Oncothyreon Inc. edged higher in Thursday's trading session even as the broad market slipped. The stock closed 1.47% higher at $2.07 on above average volume of 932,973, extending its gains in the last three trading sessions to over 10%. Year-to-date, Oncothyreon's shares have gained more than 7.80%. The stock's MACD is currently trading above the signal line, which is a bullish signal. The stock broke through $2 resistance level this week, which is another strong bullish signal. Free report on ONTY can be accessed by registering at  

Shares of biotechnology company, Zogenix Inc., rallied in Thursday's trading session, ending the day 10% higher at $1.87 on above average volume of 9.45 million. The stock has now gained more than 46% in the last three trading sessions. Zogenix's shares have broken through some key technical levels as a result of the rally this week. Register with StockCall and download the research on ZGNX for free at  

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.


PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.